What question did this study set out to answer?

To evaluate the efficacy and safety of oral metformin therapy for managing TIH in pediatric patients with ALL.

March 15, 2026

Use of Oral Metformin Therapy for Therapy‐Induced Hyperglycemia in Pediatric Patients With Acute Lymphoblastic Leukemia

Key Points

To evaluate the efficacy and safety of oral metformin therapy for managing TIH in pediatric patients with ALL.
Pediatric patients with acute lymphoblastic leukemia were treated with oral metformin.
The study assessed the incidence of non-severe hyperglycemia and insulin therapy reliance during treatment phases.
73.4% of patients could avoid insulin therapy during induction.
68.1% of patients could avoid insulin therapy during re-induction.

Abstract

Oral metformin proved to be a safe and effective first-line option for managing TIH in pediatric ALL. Insulin therapy could be avoided in majority of the patients (73.4% in induction, 68.1% in re-induction), making this drug an attractive first-line option for children with treatment-induced non-severe hyperglycemia.

Bookmark

Use of Oral Metformin Therapy for Therapy‐Induced Hyperglycemia in Pediatric Patients With Acute Lymphoblastic Leukemia

Key Points

Abstract

Cite This Study